IP Library Granted Patent US 8,088,903
Granted Patent B2
US 8,088,903 · App. 11/565,729 · Granted Jan 3, 2012

Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,088,903
App. No.
11/565,729
Granted
Jan 3, 2012
Kind
B2
Abstract

The present invention relates to flea head, nerve cord, hindgut and Malpighian tubule proteins; to flea head, nerve cord, hindgut and Malpighian tubule nucleic acid molecules, including those that encode such flea head, nerve cord, hindgut and Malpighian tubule proteins; to antibodies raised against such flea head, nerve cord, hindgut and Malpighian tubule proteins; and to compounds that inhibit flea head, nerve cord, hindgut and Malpighian tubule protein activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising proteins, nucleic acid molecules, antibodies, or protective compounds derived from proteins of the present invention as well as the use of such therapeutic compositions to protect animals from flea infestation. Also included in the present invention is the use of flea head, nerve cord, hindgut and Malpighian tubule proteins to derive inhibitory compounds.

Claims (10)

1. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:

a. a nucleic acid sequence selected from the group consisting of SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:230 and SEQ ID NO:2107, and;

b. a nucleic acid sequence fully complementary to the nucleic acid sequence of (a).

2. An isolated nucleic acid molecule selected from the group consisting of:

a. a nucleic acid molecule consisting of at least 200 contiguous nucleotides from SEQ ID NO: 23, SEQ ID NO:26, or SEQ ID NO:230;

b. a nucleic acid molecule consisting of at least 375 contiguous nucleotides from SEQ ID NO:2107; and

c. a nucleic acid sequence fully complementary to the nucleic acid sequence of (a) or (b).

3. The isolated nucleic acid molecule of claim 2 , wherein said nucleic acid molecule consists of a nucleic acid sequence selected from the group consisting of:

a. a nucleic acid sequence selected from the group consisting of SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:230 and SEQ ID NO:2107, and;

b. a nucleic acid sequence fully complementary to the nucleic acid sequence of (a).

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Dec 14, 2023
From: JPMORGAN CHASE BANK, N.A.
To: HESKA CORPORATION; DIAMOND ANIMAL HEALTH, INC.; HESKA IMAGING, LLC
Reel/Frame 066012/0887 →
SECURITY INTEREST Recorded Oct 24, 2017
From: HESKA CORPORATION; DIAMOND ANIMAL HEALTH, INC.; HESKA IMAGING, LLC
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 044636/0972 →